UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 3, 2012

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756 (Commission File Number)

Delaware

(State or Other Jurisdiction of Incorporation)

94-3023969 (I.R.S. Employer Identification No.)

932 Southwood Boulevard Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

(775) 832-8500

(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On May 3, 2012, PDL BioPharma, Inc. (the Company) issued a press release announcing the financial results for the first quarter ended March 31, 2012. A copy of this earnings release is attached hereto as Exhibit 99.1. The Company will host an earnings call and webcast on May 3, 2012, during which the Company will discuss its financial results for the first quarter ended March 31, 2012.

Item 7.01 Regulation FD Disclosure.

Presentation Materials

On May 3, 2012, the Company posted to its website a set of presentation materials that it will use during its earnings call and webcast to assist participants with understanding the Company's financial results. A copy of this presentation is attached hereto at Exhibit 99.2

Information Sheet

On May 3, 2012, the Company distributed to analysts covering the Company's securities a summary of certain information regarding the Company's net income, non-GAAP net income, dividends, convertible notes, product development, and licensed product development and sales (the Information Sheet) to assist those analysts in valuing the Company's securities. Copies of the Information Sheet and its associated tables are attached hereto as Exhibits 99.3 and 99.4, respectively.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibits, is furnished pursuant to Items 2.02 and 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Cautionary Statements

This filing includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company's royalty assets or business are disclosed in the "Risk Factors" contained in the Company's Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.

Emilorervor	
99.1	Press Release
99.2	Presentation
99.3	Information Sheet
99.4	Tables to Information Sheet

Description

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC. (Company)

By: /s/ John P. McLaughlin

John P. McLaughlin President, Chief Executive Officer and Acting Chief Financial Officer

Dated: May 3, 2012

EXHIBIT INDEX

Description

Exhibit No.

Press Release 99.1 99.2 99.3 Presentation

Information Sheet 99.4 Tables to Information Sheet



Contacts: John McLaughlin PDL BioPharma, Inc. 775-832-8500 <u>john.mclaughlin@pdl.com</u>

Jennifer Williams Cook Williams Communications 360-668-3701 jennifer@cwcomm.org

PDL BioPharma Announces First Quarter 2012 Financial Results

INCLINE VILLAGE, NV, May 3, 2012 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2012.

Royalty revenues for the first quarter of 2012 increased five percent over the same period of 2011. Total revenues for the first quarter of 2012 were \$77.3 million, compared to \$83.3 million for the same period of 2011. Total revenue for the first quarter of 2011 included a one-time settlement payment of \$10 million from UCB Pharma.

Royalty revenues for the first quarter of 2012 are based on fourth quarter 2011 product sales by PDL's licensees. The growth in royalty revenues was driven primarily by increased royalties from fourth quarter 2011 sales of Herceptin[®], which is marketed by Genentech and Roche, Lucentis[®] and Xolair[®], which are marketed by Genentech and Novartis, and Tysabri[®], which is marketed by Elan and Biogen Idec. Royalty revenue for the first quarter is net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

General and administrative expenses for the first quarter of 2012 were \$6.9 million, compared with \$5.8 million in the same period of 2011. The increase in expenses is mainly due to expenses incurred with the tender offer and exchange transactions for the 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes) and our efforts to acquire new royalty assets.

Net income for the first quarter of 2012 was \$40.2 million, or \$0.29 per diluted share as compared with net income of \$44.5 million, or \$0.25 per diluted share in the comparable quarter of 2011. Adjusting for the non-cash interest expense associated with our Series 2012 Notes and 3.75% Convertible Senior Notes due 2015 (May 2015 Notes), non-GAAP net income for the first quarter of 2012 was \$41.8 million, or \$0.30 per diluted share, compared to non-GAAP net income of \$44.5 million, or \$0.25 per diluted share for the same period of 2011.

Net cash provided by operating activities in the first quarter of 2012 was \$17.9 million, compared with net cash used in operating activities of \$13.2 million for the first quarter of 2011. At March 31, 2012, PDL had cash, cash equivalents and investments of \$192.5 million, compared with \$227.9 million at December 31, 2011.

Recent Developments

2012 Dividends

On January 18, 2012, PDL's Board of Directors declared regular quarterly dividends of \$0.15 per share of common stock, payable on March 14, June 14, September 14 and December 14 of 2012 to stockholders of record on March 7, June 7, September 7 and December 7 of 2012, the record dates for each of the dividend payments, respectively. On March 14, 2012, PDL paid the first quarterly dividend to stockholders of record totaling \$21 million using earnings generated in the first quarter of 2012 and cash on hand.

Exchange and Retirement of Convertible Notes

In January and February 2012, PDL completed public and privately negotiated exchange transactions whereby the Company exchanged and subsequently retired \$179.0 million aggregate principal amount, representing over 99 percent of the 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), for \$179.0 million aggregate principal amount of new 2.875% Series 2012 Notes, and by doing so, eliminated 27.8 million shares of potential dilution to our stock holders. In the public exchanges, PDL made one-time cash payments of \$5.00 for each \$1,000 principal amount tendered for a total cash incentive payment of \$0.8 million. As of March 31, 2012, \$1.0 million of the February 2015 Notes and \$179.0 million of the Series 2012 Notes were outstanding.

Revenue Guidance for 2012

As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. Second quarter 2012 revenue guidance will be provided in early June.

Conference Call Details

PDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, May 3, 2012.

To access the live conference call via phone, please dial (877) 677-9122 from the United States and Canada or (708) 290-1401 internationally. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through May 10, 2012, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 75297323.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at <u>http://www.pdl.com</u> and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit <u>www.pdl.com</u>.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS DATA (Unaudited) (In thousands, except per share amounts)

		onths Ended rch 31,
	2012	2011
Revenues:		
Royalties	\$ 77,344	
License and other	· · · · · · · · · · · · · · · · · · ·	10,000
Total revenues	77,344	83,336
General and administrative expenses	6,945	5,779
Operating income	70,399	77,557
Non-operating expense, net		
Interest and other income	90) 175
Interest expense	(8,700) (9,154)
Non-operating expense, net	(8,610	
Income before income taxes	61,789	
Income tax expense	21,605	
Net income	\$ 40,184	\$ 44,545
Net income per share		
Basic	\$ 0.29	\$ 0.32
Diluted	\$ 0.29	\$ 0.25
Cash dividends declared per common share	\$ 0.60	\$ 0.60
Weighted average shares outstanding		
Basic	139,680	139,640
Diluted	140,204	
Dutt	140,20-	104,334

PDL BIOPHARMA, INC. RECONCILIATION OF GAAP FINANCIAL INFORMATION TO NON-GAAP (Unaudited) (In thousands, except per share amounts)

		Three Months Ended March 31,		March 31,
	2012		2011	
Net income	\$	40,184	\$	44,545
Add Back:				
Amortization of Series 2012 Notes and May 2015 Notes debt discount, net of estimated taxes		1,596		-
Non-GAAP net income		41,780		44,545
Add back interest expense for implied conversion of convertible notes included in determination of fully diluted shares, net				
of estimated taxes		27		1,275
Non-GAAP income used to compute non-GAAP net income per diluted share	\$	41,807	\$	45,820
Shares used to compute non-GAAP net income per diluted share		140,204		184,954
· ·				
Non-GAAP net income per diluted share	\$	0.30	\$	0.25
	•	0.00	¥	0.20

PDL BIOPHARMA, INC. GENERAL AND ADMINISTRATIVE EXPENSE DATA (Unaudited) (In thousands)

]	Three Months I	Ended Ma	rch 31,
(Dollars in thousands)	2012		2011	
Compensation and benefits	\$	1,124	\$	942
Legal expense		3,529		3,495
Professional services		1,029		568
Stock-based compensation		204		50
All Other		1,059		724
Total general and administrative expenses	\$	6,945	\$	5,779

PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA (Unaudited) (In thousands)

	Mar	rch 31, 2012	De	cember 31, 2011
Cash, cash equivalents and investments	\$	192,512	\$	227,946
Total assets	\$	234,963	\$	269,471
Non-recourse notes payable	\$	69,531	\$	93,370
Convertible notes payable	\$	302,241	\$	316,615
Total stockholders' deficit	\$	(243,780)	\$	(204,273)

PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA (Unaudited) (In thousands)

		Three Months En March 31,	nded
	201	2	2011
Net income	\$	40,184 \$	44,545
Adjustments to reconcile net income to net cash provided by operating activities		6,215	2,409
Changes in assets and liabilities		(28,503)	(60,106)
Net cash provided by operating activities	\$	17,896 \$	(13,152)

PDL BIOPHARMA, INC. MIX OF EX-U.S. SALES AND EX-U.S.-BASED MANUFACTURING AND SALES (Unaudited)

		Three Months I March 31,	
		2012	2011
Avastin			
	% Ex-U.S. Sold	57%	56%
	% Ex-U.Sbased Manufactured and Sold	27%	19%
Herceptin			
	% Ex-U.S. Sold	70%	71%
	% Ex-U.Sbased Manufactured and Sold	35%	40%
Lucentis			
	% Ex-U.S. Sold	60%	57%
	% Ex-U.Sbased Manufactured and Sold	0%	0%
Xolair			
	% Ex-U.S. Sold	40%	39%
	% Ex-U.Sbased Manufactured and Sold	40%	39%





First Quarter 2012 Financial Results Conference Call May 3, 2012

Forward Looking Statements

This presentation contains forward-looking statements, including PDL's expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities.

Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

- The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
- The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus manufactured or sold in the U.S.;
- The ability of PDL's licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;
- Changes in any of the other assumptions on which PDL's projected royalty revenues are based;
- Changes in foreign currency rates;
- Positive or negative results in PDL's attempt to acquire royalty-related assets;
- The outcome of pending litigation or disputes, including PDL's current dispute with Genentech related to ex-U.S. sales of Genentech licensed products; and
- > The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual and quarterly reports filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at <u>www.pdl.com</u>. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this presentation are qualified in their entirety by this cautionary statement.



Bruce Tomlinson: VP & Chief Financial Officer

- More than 20 years of financial management experience
- Most recently chief accounting officer, vice president of finance and corporate controller of InterMune
- Experience in convertible debt transactions, tax structuring and financial negotiations for partnering
- B.A. in economics and a CPA
- Will start with PDL on June 11, 2012



First Quarter 2012 Overview

	Quarter Ended March 31				
	(In thousands, exc	ept per share amounts)			
	2012	2011			
Royalty revenues	\$ 77,344	\$ 73,336			
G&A Expenses	6,945	5,779			
Operating income	70,399	77,557			
Interest expense	(8,700)	(9,154)			
Income before income taxes	61,789	68,578			
Income tax expense	21,605	24,033			
Net income	40,184	44,545			
Net income per share - Basic	\$0.29	\$0.32			
Net income per share - Diluted	\$0.29	\$0.25			
	March 31, 2012	Dec. 31, 2011			
Cash, cash equivalents and investments	\$192,512	\$227,946			
Total assets	\$234,963	\$269,471			
Total debt carrying value	\$371,772	\$409,985			

Slide 4

\$PDL BioPharma

First Quarter 2012 Non-GAAP EPS

Quarter Ended March 31

(In thousands, except p	er share amounts)	
2012	2011	
		Non-GAAP Diluted EPS
\$40,184	\$44,545	0.40]
		0.30
1,596		0.30 - 0.25
27	1,275	0.20
	1 <u></u>	0.20 -
\$41,807	\$45,820	0.10 -
		0.00
140,204	184,954	1Q11 1Q12
\$0.30	\$0.25	
	2012 \$40,184 1,596 27 \$41,807 140,204	\$40,184 \$44,545 1,596 - 27 1,275 \$41,807 \$45,820 140,204 184,954

First quarter net income per diluted share is higher in 2012 when compared to 2011 because we eliminated 44.8 million potentially dilutive shares from the diluted earnings per share calculation by restructuring two of our convertible notes in 2011 and early 2012 to "net share settle."

Slide 5



Convertible Note Conversion Rates


In connection with the March 14, 2012 dividend payment, the conversion rates for our convertible notes increased as follows:

Convertible Notes	Conversion Rate per \$1,000 Principal Amount	Conversi	roximate on Price Per ion Share	Effective Date	ncipal Balance Dutstanding
May 2015 Notes	139.2165	\$	7.18	March 5, 2012	\$ 155,250,000
Series 2012 Notes	159.098	\$	6.29	March 5, 2012	\$ 179,000,000
February 2015 Notes	159.098	\$	6.29	March 8, 2012	\$ 1,000,000



Ex-US Manufacturing & Sales

- Roche is moving some manufacturing ex-US which may result in higher royalties to PDL due to the flat 3% royalty for Genentech Products made and sold ex-US
 - > Current production at Penzburg (Herceptin) and Basel (Avastin) plants
 - In June 2011, Roche completed 191 million SFr upgrade and expansion of Penzberg facility
 - > Two new plants in Singapore (CHO = antibody and e. coli = antibody fragment)



Percent of Net Worldwide Sales

Slide 7



Investment Highlights

- Strong historic revenue growth from approved products
- Potential for additional indications from existing products, new product approvals and purchase of new revenue generating assets
- Potential to grow and diversify revenues with the addition of new royalty assets
- Significantly reduced expenses with no R&D burn
- Liquidity volume averages 1.5 million shares/day

Return to stockholders

- > 2011: paid regular, quarterly dividends totaling \$0.60/share
- > 2012: paid regular, quarterly dividend of \$0.15/share on March 14, and will pay the same amount in dividends on June 14, September 14 and December 14

Slide 8



Following are some of the key points regarding PDL's first quarter 2012 financial and business results.

GAAP and Non-GAAP Net Income

Net income for the first quarter of 2012 was \$40.2 million or \$0.29 per diluted share as compared with a net income of \$44.5 million or \$0.25 per diluted share for the same period of 2011. First quarter net income per diluted share is higher in 2012 when compared to 2011 because we eliminated 44.8 million dilutive shares from the diluted earnings per share calculation by restructuring two of our convertible notes in 2011 and early 2012 to "net share settle."

• Non-GAAP net income for the first quarter of 2012 was \$41.8 million, or \$0.30 per diluted share, compared to non-GAAP net income of \$44.5 million, or \$0.25 per diluted share for the first quarter of 2011.

These non-GAAP financial measures exclude the effect of imputed non-cash interest on our "net-share" settled convertible notes, net of estimated taxes, from GAAP net income. We believe this exclusion facilitates comparison to PDL's cash operating results.

2012 Dividends

- We declared a regular, quarterly dividend of \$0.15 per share of common stock payable on March 14, June 14, September 14 and December 14 to stockholders of record on March 7, June 7, September 7 and December 7.
- We paid \$0.15 per share of common stock, or \$21.0 million, to our stockholders on March 14, 2012, to stockholders of record on March 7, 2012, as part of our regular, quarterly dividend policy for 2012.

Adjustments to Convertible Notes Conversion Rates

- The conversion rate for our Convertible Senior Notes due February 15, 2015 (February 2015 Notes) was adjusted to 159.098 shares of common stock per \$1,000 principal amount, or a conversion price of approximately \$6.29 per share, effective March 8, 2012.
- The conversion rate for our 3.75% Senior Convertible Notes due May 1, 2015 (May 2015 Notes), was adjusted to 139.2165 shares of common stock per \$1,000 principal amount, or a conversion price of approximately \$7.18 per share, effective March 5, 2012.
- The conversion rate for our 2.875% Series 2012 Convertible Notes due February 15, 2015 (Series 2012 Notes) is 159.098 shares of common stock per \$1,000 principal amount, or a conversion price of approximately \$6.29 per share, effective March 5, 2012.

Updates on Approved Royalty Bearing Products

<u>ACTEMRA[®]/RoACTEMRA (tocilizumab):</u>

- On March 1, 2012, Genentech announced positive preliminary results showing that patients who received Actemra as monotherapy achieved a significantly greater reduction in disease activity (assessed by the mean change of DAS28) after 24 weeks than those given Humira monotherapy.
 - Statistical significance was also achieved for key secondary endpoints including DAS28 remission and low disease activity, ACR20, 50 and 70.

<u>HERCEPTIN[®] (trastuzumab):</u>

• On March 23, 2012, Roche and Genentech announced results from the Phase III HannaH study in women with HER2-positive early breast cancer showing that subcutaneous (under the skin) injection is as effective as intravenous administration.

<u>TYSABRI[®] (natalizumab)</u>:

- On April 26, 2012, Biogen Idec and Elan Corporation, plc reported results from several studies of TYSABRI evaluating its long-term safety and efficacy in the treatment of multiple sclerosis (MS) across the course of disease and impact on MS-related symptoms such as fatigue. These data, as well as data relating to the companies' risk stratification algorithm as a way to help enable individual benefit risk assessment for patients with MS, were accepted for presentation at the 64th Annual Meeting of the American Academy of Neurology (AAN).
- As of March 2012, Biogen Idec estimates that approximately 66,600 patients were on commercial and clinical TYSABRI therapy worldwide.

Updates on Selected Development Stage Potential Royalty Bearing Products

BAPINEUZUMAB:

An April 2, 2012, publication in the Archives of Neurology indicated that bapineuzumab might lower a marker of Alzheimer's in the spinal fluid of patients with mild to moderate disease.

<u>T-DM1</u>:

On March 29, 2012, Roche and Genentech reported topline results of EMILIA, the first randomized Phase III study of trastuzumab emtansine (T-DM1). The study
showed that patients with HER2-positive metastatic breast cancer who received T-DM1 lived significantly longer without their disease getting worse compared to those
who received lapatinib plus Xeloda[®] (capecitabine).

Forward-looking Statements

This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission, and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

```
###
```

Royalty Revenue by Product (\$ in 000's) *

Avastin		Q1	Q2	Q3	Q4	Total
	2012	23,215	_			23,215
	2011	22,283	41,967	23,870	22,886	111,006
	2010	16,870	44,765	29,989	24,922	116,547
	2009	13,605	35,161	21,060	15,141	84,966
	2008	9,957	30,480	19,574	12,394	72,405
	2007	8,990	21,842	17,478	9,549	57,859
	2006	10,438	15,572	15,405	12,536	53,952
Herceptin		Q1	Q2	Q3	Q4	Total
	2012	25,702	-	-	-	25,702
	2011	25,089	42,209	31,933	21,812	121,042
	2010	23,402	38,555	27,952	25,441	115,350
	2009	16,003	32,331	26,830	18,615	93,779
	2008	14,092	34,383	28,122	20,282	96,880
	2007	19,035	28,188	22,582	14,802	84,608
	2006	15,142	19,716	21,557	20,354	76,769
Lucentis		Q1	Q2	Q3	Q4	Total
	2012	10,791	-	-	-	10,791
	2011	8,878	24,313	12,157	10,750	56,099
	2010	7,220	19,091	10,841	8,047	45,198
	2009	4,621	12,863	8,123	6,152	31,759
	2008	3,636	11,060	7,631	4,549	26,876
	2007 2006	2,931	6,543	6,579	3,517	19,570
	2006	-	-	289	3,335	3,624
Xolair		Q1	Q2	Q3	Q4	Total
	2012	5,447	-	-	-	5,447
	2011	4,590	7,621	5,916	5,823	23,949
	2010	3,723	6,386	4,980	4,652	19,741
	2009	2,665	5,082	4,085	3,722	15,553
	2008	1,488	4,866	3,569	2,927	12,850
	2007	1,684	3,942	3,332	2,184	11,142
	2006	2,263	2,969	3,041	2,495	10,768
Tysabri		Q1	Q2	Q3	Q4	Total
	2012	11,233	-	-	-	11,233
	2011	9,891	10,796	11,588	11,450	43,725
	2010	8,791	8,788	8,735	9,440	35,754
	2010 2009	8,791 6,656	8,788 7,050	8,735 7,642	9,440 8,564	35,754 29,912
	2010 2009 2008	8,791 6,656 3,883	8,788 7,050 5,042	8,735 7,642 5,949	9,440 8,564 6,992	35,754 29,912 21,866
	2010 2009 2008 2007	8,791 6,656 3,883 839	8,788 7,050 5,042 1,611	8,735 7,642 5,949 2,084	9,440 8,564 6,992 2,836	35,754 29,912 21,866 7,370
	2010 2009 2008	8,791 6,656 3,883 839 -	8,788 7,050 5,042 1,611 -	8,735 7,642 5,949 2,084 -	9,440 8,564 6,992 2,836 237	35,754 29,912 21,866 7,370 237
Actemra	2010 2009 2008 2007 2006	8,791 6,656 3,883 839 - Q1	8,788 7,050 5,042 1,611	8,735 7,642 5,949 2,084	9,440 8,564 6,992 2,836	35,754 29,912 21,866 7,370 237 Total
Actemra	2010 2009 2008 2007 2006 2012	8,791 6,656 3,883 839 - Q1 1,705	8,788 7,050 5,042 1,611 - Q2	8,735 7,642 5,949 2,084 - Q3	9,440 8,564 6,992 2,836 237 Q4	35,754 29,912 21,866 7,370 237 Total 1,705
<u>Actemra</u>	2010 2009 2008 2007 2006 2012 2012 2011	8,791 6,656 3,883 839 - Q1 1,705 913	8,788 7,050 5,042 1,611 - Q2 - 1,136	8,735 7,642 5,949 2,084 - Q3 	9,440 8,564 6,992 2,836 237 Q4 1,460	35,754 29,912 21,866 7,370 237 Total 1,705 4,910
<u>Actemra</u>	2010 2009 2008 2007 2006 2012 2012 2011 2010	8,791 6,656 3,883 839 - Q1 1,705 913 1,587	8,788 7,050 5,042 1,611 - Q2 - 1,136 237	8,735 7,642 5,949 2,084 - Q3 - 1,401 315	9,440 8,564 6,992 2,836 237 Q4 	35,754 29,912 21,866 7,370 237 Total 1,705 4,910 2,827
<u>Actemra</u>	2010 2009 2008 2007 2006 2012 2012 2011 2010 2009	8,791 6,656 3,883 839 - Q1 1,705 913 1,587 585	8,788 7,050 5,042 1,611 - Q2 - 1,136 237 537	8,735 7,642 5,949 2,084 - - - - - - - - - - - - - - - - - - -	9,440 8,564 6,992 2,836 237 Q4 	35,754 29,912 21,866 7,370 237 Total 1,705 4,910 2,827 3,228
<u>Actemra</u>	2010 2009 2008 2007 2006 2012 2012 2011 2010	8,791 6,656 3,883 839 - Q1 1,705 913 1,587	8,788 7,050 5,042 1,611 - Q2 - 1,136 237	8,735 7,642 5,949 2,084 - Q3 - 1,401 315	9,440 8,564 6,992 2,836 237 Q4 	35,754 29,912 21,866 7,370 237 Total 1,705 4,910 2,827

* As reported to PDL by its licensees

Totals may not sum due to rounding

Reported Net Sales Revenue by Product (\$ in 000's) *

Avastin		Q1	Q2	Q3	Q4	Total
	2012	1,502,757	-			1,502,757
	2011	1,597,461	1,582,705	1,581,095	1,469,994	6,231,255
	2010	1,506,788	1,596,892	1,594,707	1,646,218	6,344,605
	2009	1,345,487	1,295,536	1,439,730	1,514,053	5,594,806
	2008	980,715	1,084,930	1,180,427	1,239,382	4,485,454
	2007	678,068	746,587	797,013	875,084	3,096,752
	2006	439,318	516,052	570,551	592,897	2,118,817
Herceptin		Q1	Q2	Q3	Q4	Total
	2012	1,515,255				1,515,255
	2011	1,391,568	1,559,975	1,642,898	1,432,771	6,027,211
	2010	1,270,846	1,349,512	1,300,934	1,409,310	5,330,602
	2009	1,210,268	1,133,993	1,226,435	1,278,626	4,849,323
	2008	1,105,426	1,195,215	1,211,982	1,186,806	4,699,428
	2007	891,761	949,556	979,602	1,015,033	3,835,952
	2006	529,585	659,719	761,099	803,576	2,753,979
Lucentis		Q1	Q2	Q3	Q4	Total
	2012	1,079,092	-			1,079,092
	2011	887,757	943,418	1,052,809	1,075,015	3,958,999
	2010	721,967	698,890	745,376	804,684	2,970,917
	2009	462,103	469,736	555,296	615,212	2,102,347
	2008	363,615	393,682	460,167	454,922	1,672,386
	2007	224,820	219,579	299,995	322,300	1,066,695
	2006		-	10,689	157,742	168,431
Xolair		Q1	Q2	Q3	Q4	Total
	2012	310,234				310,234
	2011	267,754	277,642	310,874	314,911	1,171,182
	2010	228,859	225,878	251,055	263,389	969,179
	2009	184,669	181,086	211,006	219,693	796,454
	2008	137,875	169,521	177,179	183,753	668,329
	2007	129,172	130,700	144,250	147,754	551,876
	2006	95,241	99,354	112,608	118,002	425,204
Fysabri		Q1	Q2	Q3	Q4	Total
	2012	374,430	_			374,430
	2011	329,696	356,876	388,758	381,618	1,456,948
	2010	293,047	287,925	293,664	316,657	1,191,292
	2009	221,854	229,993	257,240	285,481	994,569
	2008	129,430	163,076	200,783	233,070	726,359
	2007	30,468	48,715	71,972	94,521	245,675
	2006	-	-	-	7,890	7,890
Actemra		Q1	Q2	Q3	Q4	Total
	2012	56,662	-	-		56,662
	2011	30,433	35,370	46,709	48,671	161,183
	2010	52,908	5,405	10,493	22,919	91,725
	2009	19,504	17,920	30,313	39,888	107,625
		10,001				
		1 452	1 377	5 981	12 305	21 115
	2008 2007	1,452	1,377	5,981	12,305 1,137	21,115 1,137

* As reported to PDL by its licensees Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis (\$ in 000's) *

US Made & Sold 900,139 709,967 688,966 664,878 662,224 US Made & Sold 430,533 307,941 314,028 304,155 440,035 440,037 us Made & Sold 430,533 307,941 134,028 304,155 409,296 401,896 US Made & Sold 2696 1997,441 1,882,705 1,881,005 1,469,994 1,502,757 US Made & Sold 2596 3676 3576 3776 2696 3076 US Made & Sold 2696 1996 2096 2111-Q2 2011-Q4 2012-Q1 US Made & Sold 425,303 422,053 642,670 495,066 612,998 235,353 ex-US Made & Sold 3076 2396 2396 2376 33771 1,515,255 US Made & Sold 3076 3096 419,05 1,642,898 1,642,898 1,433,151 459,620 US Made & Sold 3096 3096 4196 3096 4396 3376 US Made & Sold 3090 3097 <th>Avastin Sales</th> <th></th> <th>2010 - Q4</th> <th>2011 - Q1</th> <th>2011 - Q2</th> <th>2011 - Q3</th> <th>2011 - Q4</th> <th>2012 - Q1</th>	Avastin Sales		2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1
ex-US Made & Sold 430,503 307,941 314,028 304,155 409,286 401,896 US Made & Sold Total 1,666,218 1,597,461 1,582,075 1,511,095 1,469,994 1,469,994 1,469,994 1,469,994 1,469,994 1,469,994 1,469,994 43% 43% 43% 43% 43% 43% 33% 26% 30% 33% 26% 30% 20% 19% 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 2018 455,995 445,595 445,3168 455,995 154,2498 1,432,771 1,515,255 108 33%	US Made & Sold		800,139	708,539	719,967	688,966	684,878	652,824
Total 1,646,218 1,597,461 1,582,705 1,469,994 1,502,757 US Made & Sold 25% 36% 33% 37% 26% 39% US Made & Sold 25% 36% 33% 37% 26% 39% LS Made & Sold 26% 19% 20% 19% 2011-Q1 2011-Q2 2011-Q4 2012-Q1 2015 2011-Q3 2011-Q4 2012-Q1 2015 445,395 445,395 445,395 445,395 443,3492 534,492 537,83 537,85 537,492 537,83 537,85 537,85 537,85 537,85 537,85 537,85 537,85 534,492	US Made & ex-US Sold		415,576	580,981	548,710	587,975	375,830	448,037
US Made & Sold Mar 49% 44% Mar 49%	ex-US Made & Sold		430,503	307,941	314,028	304,155	409,286	401,896
US Made & ex-US Sold 25% 36% 35% 37% 26% 30% VS Made & Sold 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q4 2012 - Q1 US Made & Sold 416,611 409,954 442,903 445,395 445,305 453,168 456,920 US Made & Sold 425,303 423,053 642,670 495,086 612,908 523,836 v-US Made & Sold 558,661 474,402 702,416 366,695 534,982 US Made & Sold 30% 29% 27% 32% 30% US Made & Sold 30% 30% 41% 30% 433,93 US Made & Sold 30% 29% 27% 32% 30% US Made & Sold 30% 30% 43% 26% 35% Lacentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q2 2012 - Q1 US Made & Sold 443,773 509,307 533,745 630,474 646,131 645,665 v-US Made & Sold 0		Total	1,646,218	1,597,461	1,582,705	1,581,095	1,469,994	1,502,757
ex-US Made & Sold 26% 19% 20% 19% 28% 27% Herceptin Sales 2010 - Q4 2011 - Q1 442,903 443,395 453,168 456,020 US Made & Sold 455,03 423,033 424,2603 445,395 453,168 456,020 US Made & Sold 567,396 558,661 474,402 702,416 366,695 553,492 US Made & Sold 30% 29% 28% 27% 32% 30% US Made & Sold 30% 29% 28% 27% 32% 30% US Made & Sold 30% 29% 29% 27% 32% 30% US Made & Sold 300% 41% 30% 43% 26% 35% ex-US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & Sold 443,773 509,307 533,745 63,674 646,131 645,665 US Made & Sold 45% 43% 43% 40% 40% <td>US Made & Sold</td> <td></td> <td>49%</td> <td>44%</td> <td>45%</td> <td>44%</td> <td>47%</td> <td>43%</td>	US Made & Sold		49%	44%	45%	44%	47%	43%
Herceptin Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q3 2012 - Q1 2012 - Q1 US Made & Sold 416,611 409,854 442,903 445,395 445,395 453,168 456,920 US Made & Sold 557,396 558,661 474,402 702,416 366,695 533,383 ex-US Made & Sold 30% 29% 28% 77% 322% 30% US Made & Sold 30% 29% 28% 27% 32% 30% US Made & Sold 30% 30% 41% 30% 42% 30% 35% US Made & Sold 30% 40% 30% 43% 26% 35% Lucentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 360,911 378,451 409,674 422,335 422,884 433,428 US Made & Sold 437,73 509,307 53,3745 630,474 646,131 645,665 ex-US Ma	US Made & ex-US Sold		25%	36%	35%	37%	26%	30%
US Made & Sold 416,611 409,853 442,903 445,395 453,168 456,920 US Made & ex-US Sold 425,303 423,053 642,670 495,086 612,908 523,353 ex-US Made & Sold 567,396 558,661 474,402 702,416 366,695 534,982 US Made & Sold 30% 29% 29% 27% 32% 39% 30% 43% 35% 632,693 35% 632,693 30% 30% 43% 32% 30% 30% 30% 43% 32% 35% 5% 35% 35% 32% 33% 433,428 433,428 433,428	ex-US Made & Sold		26%	19%	20%	19%	28%	27%
US Made & ex-US Sold 423,003 423,0053 642,670 495,086 612,008 523,353 ex-US Made & Sold 567,396 558,661 474,402 702,416 366,695 534,982 US Made & Sold 30% 29% 28% 27% 32% 30% US Made & Sold 30% 29% 28% 27% 32% 30% US Made & Sold 30% 40% 30% 44% 30% 43% 35% Lucentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & Sold 4437,73 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold 45% 43% 43% 43% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 40% 464,616 454,3428 433,428 433,428 40% 40% 40% <td>Herceptin Sales</td> <td></td> <td>2010 - Q4</td> <td>2011 - Q1</td> <td>2011 - Q2</td> <td>2011 - Q3</td> <td>2011 - Q4</td> <td>2012 - Q1</td>	Herceptin Sales		2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1
ex-US Made & Sold $557,396$ $558,661$ $474,402$ $702,416$ $366,695$ $534,982$ US Made & Sold 300% $1,391,568$ $1,559,975$ $1,642,898$ $1,432,771$ $1,515,255$ US Made & Sold 300% 28% 22% 32% 33% US Made & Sold 300% 30% 41% 30% 43% 26% 35% Lucentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q4 2012 - Q1 US Made & Sold $360,911$ $378,451$ $409,674$ $422,335$ $428,884$ $433,428$ US Made & Sold $443,773$ $509,307$ $533,745$ $630,474$ $646,131$ $645,665$ ex-US Made & Sold $437,773$ $509,307$ $533,745$ $630,474$ $646,131$ $660,696$ US Made & Sold $437,773$ $509,307$ $533,745$ $630,474$ $646,131$ $645,665$ uS Made & Sold $1070,010$ $164,291$ $107,608$ $10,75,015$ $1,079,092$ US Made & Sold $170,001$ $164,621$ $167,608$ <td>US Made & Sold</td> <td></td> <td>416,611</td> <td>409,854</td> <td>442,903</td> <td>445,395</td> <td>453,168</td> <td>456,920</td>	US Made & Sold		416,611	409,854	442,903	445,395	453,168	456,920
Total 1,409,310 1,391,568 1,559,975 1,642,898 1,432,771 1,515,255 US Made & cx-US Sold 30% 29% 28% 27% 32% 30% US Made & cx-US Sold 30% 30% 41% 30% 43% 35% Lucentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & Sold 443,773 509,307 533,745 630,474 646,131 645,655 ex-US Made & Sold 433,773 509,307 533,745 630,474 646,131 645,666 US Made & Sold 45% 43% 443% 40% 40% 40% US Made & Sold 45% 43% 43% 40% 40% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60% 60%<	US Made & ex-US Sold		425,303	423,053	642,670	495,086	612,908	
US Made & Sold 30% 29% 28% 27% 32% 32% 30% 30% 30% 30% 41% 30% 43% 32% 32% 32% 32% 32% 32% 32% 32% 32% 3	ex-US Made & Sold		567,396	558,661	474,402	702,416	366,695	534,982
US Made & ex-US Sold 30% 41% 30% 43% 35% ex-US Made & Sold 40% 40% 30% 43% 26% 33% Lucents Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & Sold 443,773 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold 443,773 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold 443,773 5757 943,418 1,052,809 1,075,015 1,079,092 US Made & Sold 43% 43% 43% 40% 60%		Total	1,409,310	1,391,568	1,559,975	1,642,898	1,432,771	1,515,255
ex-US Made & Sold 40% 40% 30% 43% 26% 33% Lucentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & Sold 443,773 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold -	US Made & Sold		30%	29%	28%	27%	32%	30%
Lucentis Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & Sold 443,773 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold - <td>US Made & ex-US Sold</td> <td></td> <td>30%</td> <td>30%</td> <td>41%</td> <td>30%</td> <td>43%</td> <td>35%</td>	US Made & ex-US Sold		30%	30%	41%	30%	43%	35%
US Made & Sold 360,911 378,451 409,674 422,335 428,884 433,428 US Made & ex-US Sold 443,773 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold - </td <td>ex-US Made & Sold</td> <td></td> <td>40%</td> <td>40%</td> <td>30%</td> <td>43%</td> <td>26%</td> <td>35%</td>	ex-US Made & Sold		40%	40%	30%	43%	26%	35%
US Made & ex-US Sold 443,773 509,307 533,745 630,474 646,131 645,665 ex-US Made & Sold -	Lucentis Sales		2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1
ex-US Made & Sold -	US Made & Sold		360,911	378,451	409,674	422,335	428,884	433,428
Total 804,684 887,757 943,418 1,052,809 1,075,015 1,079,092 US Made & Sold 45% 43% 43% 40% 40% 40% US Made & Sold 55% 57% 57% 60% 60% 60% ex-US Made & Sold 0% 0% 0% 0% 0% 0% 0% Xolar Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & Sold 93,388 103,133 110,034 126,037 126,184 124,729 US Made & Sold 65% 61% 60% 59% 60% 60% US Made & Sold 35% 39% 40% 41% 40% 40% US Made & Sold 1,747,662 1,661,465 1,740,152 <t< td=""><td>US Made & ex-US Sold</td><td></td><td>443,773</td><td>509,307</td><td>533,745</td><td>630,474</td><td>646,131</td><td>645,665</td></t<>	US Made & ex-US Sold		443,773	509,307	533,745	630,474	646,131	645,665
US Made & Sold 45% 43% 43% 40% 40% 40% US Made & sold 55% 57% 57% 60% 60% 60% ex-US Made & Sold 0% 0% 0% 0% 0% 0% 0% Xolair Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & Sold 93,388 103,133 110,034 126,037 126,184 124,729 US Made & Sold 65% 61% 60% 55% 60% 60% US Made & Sold 65% 61% 60% 59% 60% 60% US Made & Sold 65% 38% 2011 - Q1 2011 - Q2 310,874 314,911 310,234 US Made & Sold 0% 0% 0% 0% 60% 60% US Made & Sold 1,747,662 1,661,465 1,740,152 1	ex-US Made & Sold		-	-	-	-	-	-
US Made & ex-US Sold 55% 57% 57% 60% 60% 60% ex-US Made & Sold 0% 0% 0% 0% 0% 0% 0% 0% Xolair Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & Sold 93,388 103,133 110,034 126,037 126,184 124,729 US Made & Sold 93,388 103,133 110,034 126,037 126,184 124,729 US Made & Sold 65% 61% 60% 55% 60% 60% US Made & Sold 65% 61% 60% 55% 60% 60% US Made & Sold 0% 0% 0% 0% 0% 0% 0% US Made & Sold 1,747,662 1,61 2010 - Q4 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 1,		Total	804,684	887,757	943,418	1,052,809	1,075,015	1,079,092
ex-US Made & Sold 0% 0% 0% 0% 0% 0% Xolair Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & sold 93,388 103,133 110,034 126,037 126,164 124,729 ex-US Made & Sold 93,388 103,133 110,034 126,037 1314,911 310,234 US Made & Sold 65% 61% 60% 59% 60% 60% 60% US Made & Sold 0% 0% 0% 0% 0% 0% 0% 0% US Made & Sold 05% 61% 60% 59% 60% 60% 60% US Made & Sold 0% 0% 0% 0% 0% 0% 0% US Made & Sold 1,747,662 1,661,465 1,740,152 1,741,534 1,755,657 1,728,678 US Made & Sold 1,284,652	US Made & Sold		45%	43%	43%	40%	40%	40%
Xolair Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & Sold -<	US Made & ex-US Sold		55%	57%	57%	60%	60%	60%
US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & ex-US Sold - <t< td=""><td>ex-US Made & Sold</td><td></td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td><td>0%</td></t<>	ex-US Made & Sold		0%	0%	0%	0%	0%	0%
US Made & Sold 170,001 164,621 167,608 184,837 188,728 185,505 US Made & ex-US Sold - <t< th=""><th>Xolair Sales</th><th></th><th>2010 - Q4</th><th>2011 - Q1</th><th>2011 - Q2</th><th>2011 - Q3</th><th>2011 - Q4</th><th>2012 - Q1</th></t<>	Xolair Sales		2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1
US Made & ex-US Sold -	US Made & Sold		170.001	164.621	167.608		188,728	
Total263,389267,754277,642310,874314,911310,234US Made & Sold65%61%60%59%60%60%US Made & ex-US Sold0%0%0%0%0%0%ex-US Made & Sold35%39%40%41%40%40%Total Sales2010 - Q42011 - Q12011 - Q22011 - Q32011 - Q42012 - Q1US Made & Sold1,747,6621,661,4651,740,1521,741,5341,755,6571,728,678US Made & Sold1,284,6521,513,3401,725,1251,713,5351,634,8691,617,054ex-US Made & Sold1,091,287969,735898,4641,132,608902,1651,061,607Total4,123,6014,144,5404,363,7414,587,6774,292,6914,407,339US Made & Sold42%40%40%38%41%39%US Made & ex-US Sold31%37%40%37%38%37%	US Made & ex-US Sold		-	-	-	-	-	-
US Made & Sold 65% 61% 60% 59% 60% 60% US Made & ex-US Sold 0% 0% 0% 0% 0% 0% ex-US Made & Sold 35% 39% 40% 41% 40% 40% Total Sales 2010 - Q4 2011 - Q1 2011 - Q2 2011 - Q3 2011 - Q4 2012 - Q1 US Made & Sold 1,747,662 1,661,465 1,740,152 1,741,534 1,755,657 1,728,678 US Made & Sold 1,284,652 1,513,340 1,725,125 1,713,535 1,634,869 1,617,054 ex-US Made & Sold 1,091,287 969,735 898,464 1,132,608 902,165 1,061,607 Total 4,123,601 4,144,540 4,363,741 4,587,677 4,292,691 4,407,339 US Made & Sold 42% 40% 40% 38% 41% 39% US Made & ex-US Sold 31% 37% 40% 37% 38% 37%	ex-US Made & Sold		93,388	103,133	110,034	126,037	126,184	124,729
US Made & ex-US Sold 0% <th< td=""><td></td><td>Total</td><td>263,389</td><td>267,754</td><td>277,642</td><td>310,874</td><td>314,911</td><td>310,234</td></th<>		Total	263,389	267,754	277,642	310,874	314,911	310,234
ex-US Made & Sold35%39%40%41%40%40%Total Sales2010 - Q42011 - Q12011 - Q22011 - Q32011 - Q42012 - Q1US Made & Sold1,747,6621,661,4651,740,1521,741,5341,755,6571,728,678US Made & sold1,284,6521,513,3401,725,1251,713,5351,634,8691,617,054ex-US Made & Sold1,091,287969,735898,4641,132,608902,1651,061,607Total4,123,6014,144,5404,363,7414,587,6774,292,6914,407,339US Made & Sold42%40%40%38%41%39%US Made & ex-US Sold31%37%40%37%38%37%	US Made & Sold		65%	61%	60%	59%	60%	60%
Total Sales2010 - Q42011 - Q12011 - Q22011 - Q32011 - Q42012 - Q1US Made & Sold1,747,6621,661,4651,740,1521,741,5341,755,6571,728,678US Made & ex-US Sold1,284,6521,513,3401,725,1251,713,5351,634,8691,617,054ex-US Made & Sold1,091,287969,735898,4641,132,608902,1651,061,607Total4,123,6014,144,5404,363,7414,587,6774,292,6914,407,339US Made & Sold42%40%40%38%41%39%US Made & ex-US Sold31%37%40%37%38%37%	US Made & ex-US Sold		0%	0%	0%	0%	0%	0%
US Made & Sold 1,747,662 1,661,465 1,740,152 1,741,534 1,755,657 1,728,678 US Made & ex-US Sold 1,284,652 1,513,340 1,725,125 1,713,535 1,634,869 1,617,054 ex-US Made & Sold 1,091,287 969,735 898,464 1,132,608 902,165 1,061,607 Total 4,123,601 4,144,540 4,363,741 4,587,677 4,292,691 4,407,339 US Made & Sold 42% 40% 40% 38% 41% 39% US Made & ex-US Sold 31% 37% 40% 37% 38% 37%	ex-US Made & Sold		35%	39%	40%	41%	40%	40%
US Made & ex-US Sold 1,284,652 1,513,340 1,725,125 1,713,535 1,634,869 1,617,054 ex-US Made & Sold 1,091,287 969,735 898,464 1,132,608 902,165 1,061,607 Total 4,123,601 4,144,540 4,363,741 4,587,677 4,292,691 4,407,339 US Made & Sold 42% 40% 40% 38% 41% 39% US Made & ex-US Sold 31% 37% 40% 37% 38% 37%	Total Sales		2010 - Q4	2011 - Q1	2011 - Q2	2011 - Q3	2011 - Q4	2012 - Q1
ex-US Made & Sold 1,091,287 969,735 898,464 1,132,608 902,165 1,061,607 Total 4,123,601 4,144,540 4,363,741 4,587,677 4,292,691 4,407,339 US Made & Sold 42% 40% 40% 38% 41% 39% US Made & ex-US Sold 31% 37% 40% 37% 38% 37%	US Made & Sold		1,747,662	1,661,465	1,740,152	1,741,534	1,755,657	1,728,678
ex-US Made & Sold 1,091,287 969,735 898,464 1,132,608 902,165 1,061,607 Total 4,123,601 4,144,540 4,363,741 4,587,677 4,292,691 4,407,339 US Made & Sold 42% 40% 40% 38% 41% 39% US Made & ex-US Sold 31% 37% 40% 37% 38% 37%	US Made & ex-US Sold		1,284,652	· · · · ·		· · ·	· · · · · · · · · · · · · · · · · · ·	
Total 4,123,601 4,144,540 4,363,741 4,587,677 4,292,691 4,407,339 US Made & Sold 42% 40% 40% 38% 41% 39% US Made & ex-US Sold 31% 37% 40% 37% 38% 37%	ex-US Made & Sold		1,091,287		898,464			1,061,607
US Made & ex-US Sold 31% 37% 40% 37% 38% 37%		Total		4,144,540				
	US Made & Sold		42%	40%	40%	38%	41%	39%
ex-US Made & Sold 26% 23% 21% 25% 21% 24%	US Made & ex-US Sold		31%	37%	40%	37%	38%	37%
	ex-US Made & Sold		26%	23%	21%	25%	21%	24%

* As reported to PDL by its licensees

Totals may not sum due to rounding